Interventional radiology is a field grounded in the use of advanced imaging techniques to guide minimally invasive procedures. By integrating angiography and CT in one location, clinicians at the Huntsman Cancer Institute can now perform comprehensive diagnostic and therapeutic interventions with unprecedented efficiency and accuracy. The dual imaging capabilities facilitate a seamless workflow where patients no longer need to be transferred between different rooms or make repeated visits for separate imaging sessions, significantly mitigating the logistical challenges and health risks associated with traditional workflows.

Angiography, a pivotal component of this suite, employs live X-ray fluoroscopy combined with a contrast agent injected into the blood vessels. This technique allows physicians to visualize the precise vascular feeding patterns of tumors. Recognizing the intricate vascular supply to malignant tissues is critical for therapies aimed at starving tumors by occluding their blood flow or delivering targeted chemotherapy or radiation directly via the bloodstream. This goal-driven approach maximizes the therapeutic effect on the tumor while sparing the surrounding healthy tissues, thereby minimizing the systemic side effects commonly seen in traditional systemic treatments like hair loss, nausea, and generalized toxicity.

Parallel to angiography, CT imaging offers high-resolution, still images that provide detailed anatomical information. Within the angio-CT suite, CT scans are instrumental in delineating the tumor’s exact location and its spatial relationship to adjacent organs. This precision facilitates interventions such as biopsy needle guidance and ablation therapies. Interventional radiologists employ CT to direct thermal ablation tools that either freeze (cryoablation) or heat (radiofrequency or microwave ablation) malignant cells, thereby destroying the tumor tissue with minimal collateral damage. This combined approach enhances clinical outcomes, particularly for tumors in anatomically challenging regions like the liver and kidneys.

Historically, performing angiography and CT-guided interventions required separate sessions or at least relocating patients between different suites, often under anesthesia, which increased patient discomfort, procedural risk, and health system costs. By housing both modalities in a single suite, the Huntsman Cancer Institute minimizes exposure to multiple anesthetic events and reduces time delays between imaging and treatment. This streamlined process allows clinicians to first use CT imaging to plan the intervention, proceed with the angiographic procedure under real-time X-ray guidance, and then immediately verify treatment efficacy via CT—all within the same setting.

Dr. Wael Saad, director of interventional radiology, emphasizes how the integrated suite enables dynamic imaging workflows. For example, clinicians can confirm the success of tumor embolization by analyzing post-procedure CT images before concluding the session. This capability ensures immediate adjustments if necessary, enhancing treatment precision and reducing the need for subsequent interventions. Such technological integration is set to revolutionize the treatment paradigm, especially for patients living in rural or underserved areas who would otherwise face burdensome travel and delayed follow-up.

The anatomical accuracy and real-time feedback provided by the angio-CT suite also improve multidisciplinary care coordination. Complex cancer cases often require the expertise of multiple specialists, including oncologists, radiologists, and surgeons. The hybrid imaging suite fosters collaborative treatment planning by furnishing comprehensive imaging data that inform decisions about the most appropriate minimally invasive therapies. Consequently, it accelerates therapeutic delivery and aligns with patient-centered care principles.

From a patient perspective, the reduction in procedural frequency, cumulative anesthesia exposure, and travel demands translate into improved safety, convenience, and overall experience. Patients who may have previously required separate visits spaced days or weeks apart can now complete critical imaging and treatment in a single appointment. This efficiency mitigates the emotional and physical toll associated with cancer treatment and provides timely feedback regarding therapeutic response, crucial elements in managing aggressive malignancies.

This angio-CT innovation particularly benefits liver and renal cancers, where targeted embolization and thermal ablation have emerged as vital therapeutic modalities. However, the suite’s capabilities extend across multiple cancer types, underscoring its versatility within interventional oncology. By enabling precise mapping and treatment of tumors in situ, the technology supports enhanced tumor control while preserving organ function and patient quality of life.

The implementation of the angio-CT suite embodies Huntsman Cancer Institute’s commitment to integrating cutting-edge technology with compassionate, patient-centered care. Dr. Charles Ray, interim chair of the Department of Radiology, characterizes this advancement as a “game changer” that elevates the standard of care through highly targeted therapies delivered with exceptional precision. This aligns with the institute’s strategic goal to pioneer minimally invasive approaches that improve clinical outcomes while reducing treatment-associated morbidity.

Officially launched on November 11, the angio-CT suite marks a significant investment in oncologic innovation for the Mountain West region. The novel application of dual imaging modalities in a single clinical space underscores the evolving role of interventional radiology in cancer treatment and symbolizes a promising future where technology and human expertise converge to redefine patient care standards.

Huntsman Cancer Institute, designated as a National Cancer Institute Comprehensive Cancer Center, serves patients across Utah, Idaho, Montana, Nevada, and Wyoming. The institute’s extensive research and clinical trials infrastructure supports ongoing innovation in cancer treatment, including the development of technologies like the angio-CT suite. By continuously expanding its capabilities, Huntsman advances a mission centered on transforming cancer diagnosis, treatment, and survivorship through scientific discovery and precision medicine.

In summary, the angio-CT suite at the University of Utah’s Huntsman Cancer Institute represents a pivotal advancement in the field of interventional oncology. By harnessing the synergistic power of angiography and CT imaging, the suite not only optimizes therapeutic efficacy but also significantly enhances the patient experience. This innovative model stands as a beacon for other institutions seeking to redefine cancer care through technology-driven, patient-focused solutions.

Subject of Research: Cancer treatment, interventional radiology, angiography, CT imaging

Article Title: Huntsman Cancer Institute Unveils Region’s First Integrated Angiography-CT Suite to Revolutionize Cancer Care

News Publication Date: November 11, 2023

Web References:

• https://healthcare.utah.edu/huntsmancancerinstitute/
• https://healthcare.utah.edu/radiology/interventional

Image Credits: Huntsman Cancer Institute

Keywords: Cancer treatments, Liver cancer, Interventional radiology, Angiography, CT imaging, Minimally invasive therapy, Tumor embolization, Thermal ablation

Osteoarthritis triggers a cascade of pathological changes in the knee joint, prominently including inflammation caused by the degradation of cartilage and surrounding tissues. This inflammation stimulates the formation of abnormal blood vessels—a process known as angiogenesis—which increases blood flow to the joint. These newly formed vessels facilitate the migration of immune cells that exacerbate inflammation and contribute to persistent pain. Genicular artery embolization targets this vascular remodeling, aiming to mitigate the pathological blood flow feeding the inflamed synovium lining the knee.

The procedure involves the targeted delivery of biocompatible hydrogel beads through an image-guided catheter inserted via a tiny incision in the thigh. These microspheres selectively occlude up to half a dozen arteries supplying the synovium, effectively cutting off the pathological blood supply and interrupting the inflammatory signaling pathways. In the recent study, over 60% of the 25 patients undergoing this therapy in Manhattan reported marked improvements in pain, function, and stiffness one year post-procedure, highlighting the clinical potential of this approach.

Published online on August 12, 2025, in the Journal of Vascular and Interventional Radiology, this prospective single-arm trial closely monitored symptomatic patients with moderate to severe knee osteoarthritis unresponsive to conventional treatments such as corticosteroid injections, arthrocentesis, platelet-rich plasma therapy, and physiotherapy. Patient-reported outcomes, including standardized surveys assessing pain, stiffness, and mobility, were coupled with biomarker analyses to objectively evaluate treatment success.

One of the most compelling findings was the significant decline in serum levels of vascular endothelial growth factor (VEGF) observed at one-year follow-up, with an average reduction of 12%. VEGF is a pivotal protein driving angiogenesis, and its decline suggests that genicular artery embolization may directly alter the pathological vascular and inflammatory milieu within the osteoarthritic joint. Similarly, levels of interleukin 1 receptor antagonist (IL-1Ra), a key modulator of inflammation, decreased by 15%, further underscoring the anti-inflammatory effects of this intervention.

Dr. Ryan Hickey, associate professor and section chief of vascular and interventional radiology at NYU Grossman School of Medicine, emphasized the broader implications of the findings. He noted that genicular artery embolization not only provides symptomatic relief but might also influence the natural history of osteoarthritis by modifying underlying disease processes. The minimally invasive nature and favorable safety profile, with mild and transient side effects limited to localized skin discoloration and minor incision discomfort, render it particularly appealing to patients contraindicated for surgery.

Patients selected for this study ranged in age from 50 to 78 years, encompassing individuals for whom total knee replacement might be premature or medically risky due to comorbidities such as obesity, uncontrolled diabetes, cardiovascular disease, or tobacco use. This procedure fills a critical therapeutic void, offering a viable alternative for those in intermediate disease stages who have failed first-line therapies.

The technical execution of genicular artery embolization leverages advanced imaging techniques—primarily fluoroscopy—to guide catheters through the femoral artery to target knee vessels precisely. The delivery of embolic material is carefully calibrated to avoid ischemic damage to surrounding tissues, underscoring the expertise required in interventional radiology to navigate the intricate vascular anatomy of the knee.

In addition to clinical assessments, the study underscores the value of incorporating biochemical biomarkers such as VEGF as objective measures of treatment efficacy. Unlike subjective pain scales, these blood tests quantify molecular changes reflective of underlying pathophysiology, potentially serving as benchmarks for future clinical trials and long-term monitoring.

The research team, led by principal investigator Dr. Bedros Taslakian, now vice chair for research at the University of Miami Miller School of Medicine, highlighted the need for larger, randomized controlled trials to validate these findings and determine the longevity of benefits derived from embolization. Understanding patient-specific predictors for response will be crucial to refining indications and optimizing outcomes.

Further investigations are underway to elucidate the precise molecular and cellular mechanisms by which vascular occlusion translates into reduced joint inflammation and pain relief. Insights gained could pave the way for combination therapies or refinements in embolic materials to enhance the durability and scope of clinical benefits.

As osteoarthritis continues to impose a growing burden on healthcare systems — with approximately 24 million new knee cases diagnosed annually in the United States alone — the development of safe, effective, and minimally invasive treatment modalities like genicular artery embolization holds transformative potential. This intervention may ultimately delay or reduce the need for joint replacement surgeries, improving quality of life for a vast patient population.

In summary, the NYU Langone Health study propels genicular artery embolization into the spotlight as a promising therapeutic frontier in osteoarthritis management. Through strategic vascular intervention and evidence-based biomarker monitoring, this technique unlocks new possibilities to address chronic pain and joint degeneration that have long challenged clinicians and patients alike.

Subject of Research: People

Article Title: A Prospective Single-Arm Trial of Genicular Artery Embolization for Symptomatic Knee Osteoarthritis: Clinical and Biomarker Outcomes

News Publication Date: 12-Aug-2025

Web References: http://dx.doi.org/10.1016/j.jvir.2025.08.009

References:
Taslakian B, Hickey R, et al. A Prospective Single-Arm Trial of Genicular Artery Embolization for Symptomatic Knee Osteoarthritis: Clinical and Biomarker Outcomes. Journal of Vascular and Interventional Radiology. 2025 Aug 12. DOI: 10.1016/j.jvir.2025.08.009.

Keywords: Osteoarthritis, Genicular Artery Embolization, Interventional Radiology, Angiogenesis, Vascular Endothelial Growth Factor, Inflammation, Knee Pain, Minimally Invasive Treatment